Last reviewed · How we verify

NCT07321314

RSV Burden in Hong Kong

Not yet recruiting Last updated 8 January 2026
What this trial tests

trial testing Serial specimen sampling in RSV in 10,000 participants. Not yet recruiting.

Timeline
1 March 2026
Primary endpoint
29 February 2028
31 August 2028

Quick facts

Lead sponsorChinese University of Hong Kong
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment10,000
Start date1 March 2026
Primary completion29 February 2028
Estimated completion31 August 2028
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with RSV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RSV infection causes significant mortality and morbidity in susceptible adults. There are many publications on the global RSV disease burden in infants and young children but data on adults are lacking with lots of knowledge gaps. Currently there is no established effective antiviral therapy for RSV. RSV vaccines have recently become available commercially but the Center for Health Protection (Hong Kong) has yet to discuss procurement of RSV vaccines for the high risk groups. Thus a prospective study to assess the disease burden of RSV infection in adults would be of great interest.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for RSV

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07321314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing